Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KALV
KALV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KALV News
Investor Rights Law Firm Investigates RE/MAX and Others
2d ago
PRnewswire
KALVISTA PHARMACEUTICALS INC: STIFEL Downgrades to Hold from Buy and Lowers Target Price to $27 from $42
2d ago
moomoo
Investor Rights Law Firm Investigates Multiple Companies
6d ago
PRnewswire
KALVISTA PHARMACEUTICALS INC: LEERINK PARTNERS LOWERS RATING TO MARKET PERFORM FROM OUTPERFORM; INCREASES TARGET PRICE TO $27 FROM $22
Apr 30 2026
moomoo
KalVista Pharmaceuticals Acquired by Italy's Chiesi Group
Apr 29 2026
Fool
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
Apr 29 2026
PRnewswire
Investigation into KalVista's Transaction with Chiesi Group
Apr 29 2026
PRnewswire
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion
Apr 29 2026
Newsfilter
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
Apr 29 2026
seekingalpha
Alpha Cognition Appoints New Board Member
Apr 20 2026
Newsfilter
KalVista Reports Interim Results of EKTERLY Clinical Trial
Mar 30 2026
NASDAQ.COM
KALVISTA PHARMACEUTICALS INC - INITIAL DATA INDICATES SEBETRALSTAT PROVIDES PROMPT AND EFFICIENT TREATMENT FOR HAE IN CHILDREN
Mar 30 2026
moomoo
KALVISTA PHARMACEUTICALS INC: STIFEL INCREASES TARGET PRICE FROM $39 TO $42
Mar 26 2026
moomoo
KalVista Pharmaceuticals Reports 2025 Fiscal Year Performance
Mar 25 2026
Yahoo Finance
KalVista Reports $49.1 Million Revenue for EKTERLY® in Eight Months
Mar 25 2026
Newsfilter
KALVISTA PHARMACEUTICALS INC - ANNOUNCES EPS OF $-2.03 FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
Mar 25 2026
moomoo
Show More News
